Trial Profile
A Phase IIb Trial of an Encapsulated Cell Therapy Product in Locally Advanced, Inoperable Pancreatic Cancer (LAPC)
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 28 Jul 2022
Price :
$35
*
At a glance
- Drugs Ifosfamide (Primary) ; Microencapsulated CYP2B1-expressing cells+ifosfamide PharmaCyte Biotech (Primary) ; Capecitabine
- Indications Pancreatic cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors PharmaCyte Biotech
Most Recent Events
- 21 Jul 2022 According to a PharmaCyte media release, the company has commenced the pilot phase of its two-phase pig study which is the last of several requirements PharmaCyte has complied with related to the requests from the U.S. Food and Drug Administration (FDA) to lift the clinical hold from this study.
- 19 Aug 2021 According to a PharmaCyte Biotech media release, the company intends to use the net proceeds from the institutional investors offerings to fully fund and conduct this study.
- 02 Aug 2021 According to a PharmaCyte Biotech media release, company announced uplist to the nasdaq capital market and launch of public offering, company intends to use the net proceeds of this offering to complete activities requested by the U.S. Food and Drug Administration (FDA) in order to address the FDA clinical hold on its Investigational New Drug application (IND) with respect to this trial and to begin to fund and conduct this trial, if and when the clinical hold on the IND is lifted.